APA (7th ed.) Citation

Artaç, M., Korkmaz, L., Karaağaç, M., Kaya, B., Poyraz, N., Özön, H., . . . Tavlı, L. (2018). A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib. Galenos Publishing House.

Chicago Style (17th ed.) Citation

Artaç, Mehmet, Levent Korkmaz, Mustafa Karaağaç, Buğra Kaya, Necdet Poyraz, Hakan Özön, Zehra Er, and Lema Tavlı. A Lung Adenocarcinoma Patient with EGFR Mutation in Exon 18 and ALK-rearrangement Who Treated with Erlotinib and Crizotinib. Galenos Publishing House, 2018.

MLA (9th ed.) Citation

Artaç, Mehmet, et al. A Lung Adenocarcinoma Patient with EGFR Mutation in Exon 18 and ALK-rearrangement Who Treated with Erlotinib and Crizotinib. Galenos Publishing House, 2018.